DuraSTARNCT07740720
A Study of the Duration of Dostarlimab in Untreated Mismatch Repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H) Locally Advanced Rectal Cancer
At risk: Primary completion moved at least 3 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Start date: Sep 17, 2026 to Dec 17, 2026 Show 6 more changesShow less
- Eligibility criteria expanded, about 12 words
- Primary endpoints: details revised at 1 of 1 entry
- Primary completion pushed from Dec 12, 2029 to Mar 13, 2030
- Enrollment increased: 90 → 100 participants
- Study completion pushed from Dec 31, 2029 to Apr 1, 2030
- Study sites: 0 to 1
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Percentage of participants who achieve clinical complete response (cCR) amongst participants who receive > 9 cycles (> 6 months) of dostarlimab monotherapy by investigator assessment
Timeframe: Up to 168 weeks
Secondary (6)
Overall cCR rate by investigator assessment
Number of participants with sustained clinical complete response at 12 months (cCR12) as assessed by investigator
Objective response rate (ORR) as assessed by investigator
Number of participants with composite cCR12 and pathologic complete response (pCR) as assessed by investigator
Time to cCR
Show 1 moreShow less
Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), immune-mediated adverse event (imAEs), and AEs leading to death or discontinuation of study intervention by severity
Arms and interventions
DostarlimabExperimental
Biologicals: Dostarlimab
Sites
1 site in 1 country
- GSK Investigational SiteFukuoka, Japan